Hybridon
Executive Summary
Worcester, Mass.-based anti-sense therapeutics R&D start-up appoints former Damon Biotech President Nigel Webb, PhD, to chairman and CEO. Former Rorer Senior VP-Operations Donald Kuhla named president.. .. ISIS Pharmaceuticals: Five-year cooperative R&D agreement with Japanese firm Eisai Company Ltd. focuses on the discovery and development of antisense oligonucleotides for potential human diagnostic and therapeutic application. Ciba-Geigy and Rhone- Poulenc are also backers of ISIS R&D.